{
    "info": {
        "nct_id": "NCT03995706",
        "official_title": "A Phase 0, Investigator Initiated Study to Determine the Bioavailability of Sacituzumab Govitecan in Breast Brain Metastasis and Glioblastoma",
        "inclusion_criteria": "* At least 18 years of age\n* Histologically or cytologically documented breast cancer (Cohort A) with known or suspected parenchymal brain metastases.\n* Recurrent glioblastoma (Cohort B) with documented progression by RANO criteria following standard combined modality treatment with radiation and temozolomide.\n* Plans to undergo craniotomy as part of standard of care. Patients emergently needing surgical debulking due to symptoms of their disease are not eligible.\n* Recovered from toxicities of prior therapy to grade 0 or 1\n* ECOG performance status ≤ 2.\n* Life expectancy of at least 3 months.\n* Acceptable liver function:\n* Bilirubin ≤ 1.5 times upper limit of normal\n* AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN);\n* Adequate renal function: calculated creatinine clearance ≥30mL/minute according to the Cockcroft and Gault formula\n* Acceptable hematologic status (without hematologic support)\n* ANC ≥1500 cells/uL\n* Platelet count ≥100,000/uL\n* Hemoglobin ≥9.0 g/dL\n* All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drug.\n* The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible.\n* The subject is unable to undergo MRI scan (eg, has pacemaker).\n* The subject has received enzyme-inducing anti-epileptic agents within 14 days of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone).\n* Patients whose only lesion undergoing resection has received stereotactic radiation within the past 3 months\n* The subject has received any of the following prior anticancer therapy:\n\n  * Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug\n  * Prior treatment with Sacituzumab Govitecan\n* Patients receiving UGT1A1 (Uridine diphosphate glucuronosyl transferase 1A1) inhibitors or inducers.\n* History of significant cardiovascular disease, defined as:\n\n  * Congestive heart failure greater than New York Heart Association (NYHA) Class II according to the NYHA Functional Classification.\n  * Unstable angina or myocardial infarction within 6 months before enrollment.\n  * Serious cardiac arrhythmia.\n* Clinically significant ECG abnormality, including:\n\n  * Marked Baseline prolonged QT/QTc interval (ie, a repeated demonstration of a QTc interval >500 ms) demonstrated on ECG at Screening.\n  * History of risk factors for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT Syndrome).\n* Any medical or other condition which, in the opinion of the Investigator, causes the subject to be medically unfit to receive Sacituzumab Govitecan, or unsuitable for any other reason.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Recurrent glioblastoma (Cohort B) with documented progression by RANO criteria following standard combined modality treatment with radiation and temozolomide.",
            "criterions": [
                {
                    "exact_snippets": "Recurrent glioblastoma (Cohort B)",
                    "criterion": "glioblastoma",
                    "requirements": [
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented progression by RANO criteria",
                    "criterion": "disease progression by RANO criteria",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "following standard combined modality treatment with radiation and temozolomide",
                    "criterion": "prior treatment with radiation and temozolomide",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": [
                                "radiation",
                                "temozolomide"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acceptable hematologic status (without hematologic support)",
            "criterions": [
                {
                    "exact_snippets": "Acceptable hematologic status",
                    "criterion": "hematologic status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        }
                    ]
                },
                {
                    "exact_snippets": "without hematologic support",
                    "criterion": "hematologic support",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recovered from toxicities of prior therapy to grade 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Recovered from toxicities of prior therapy to grade 0 or 1",
                    "criterion": "toxicities of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "grade 0",
                                "grade 1"
                            ]
                        },
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of at least 3 months.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of at least 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically documented breast cancer (Cohort A) with known or suspected parenchymal brain metastases.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically documented breast cancer (Cohort A)",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis method",
                            "expected_value": [
                                "histologically documented",
                                "cytologically documented"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "known or suspected parenchymal brain metastases",
                    "criterion": "parenchymal brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "certainty",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ANC ≥1500 cells/uL",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥1500 cells/uL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥100,000/uL",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥100,000/uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acceptable liver function:",
            "criterions": [
                {
                    "exact_snippets": "Acceptable liver function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Plans to undergo craniotomy as part of standard of care. Patients emergently needing surgical debulking due to symptoms of their disease are not eligible.",
            "criterions": [
                {
                    "exact_snippets": "Plans to undergo craniotomy as part of standard of care",
                    "criterion": "planned craniotomy",
                    "requirements": [
                        {
                            "requirement_type": "planned procedure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "standard of care"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients emergently needing surgical debulking due to symptoms of their disease are not eligible",
                    "criterion": "emergent need for surgical debulking due to symptoms",
                    "requirements": [
                        {
                            "requirement_type": "emergent need",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status ≤ 2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status ≤ 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose.",
            "criterions": [
                {
                    "exact_snippets": "All women of childbearing potential must have a negative serum pregnancy test",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception methods",
                            "expected_value": [
                                "surgical sterilization",
                                "barrier contraception with condom",
                                "barrier contraception with diaphragm in conjunction with spermicidal gel",
                                "IUD"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from entry into the study"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months after the last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin ≤ 1.5 times upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ≤ 1.5 times upper limit of normal",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "times upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function: calculated creatinine clearance ≥30mL/minute according to the Cockcroft and Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function: calculated creatinine clearance ≥30mL/minute according to the Cockcroft and Gault formula",
                    "criterion": "renal function (creatinine clearance)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/minute"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft and Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN);",
            "criterions": [
                {
                    "exact_snippets": "AST (SGOT) ... ≤ 3.0 times upper limit of normal (ULN)",
                    "criterion": "AST (SGOT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "times ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN)",
                    "criterion": "ALT (SGPT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "times ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "At least 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Unstable angina or myocardial infarction within 6 months before enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina ... within 6 months before enrollment.",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within 6 months before enrollment.",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "The subject is receiving warfarin (or other coumarin derivatives)",
                    "criterion": "use of warfarin or other coumarin derivatives",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drug",
                    "criterion": "ability to switch to low molecular weight heparin (LMWH) before the first dose of study drug",
                    "requirements": [
                        {
                            "requirement_type": "ability to switch",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject is unable to undergo MRI scan (eg, has pacemaker).",
            "criterions": [
                {
                    "exact_snippets": "The subject is unable to undergo MRI scan",
                    "criterion": "ability to undergo MRI scan",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "has pacemaker",
                    "criterion": "presence of pacemaker",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious cardiac arrhythmia.",
            "criterions": [
                {
                    "exact_snippets": "Serious cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible.",
            "criterions": [
                {
                    "exact_snippets": "evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan",
                    "criterion": "acute intracranial or intratumoral hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible",
                    "criterion": "resolving hemorrhage changes, punctate hemorrhage, or hemosiderin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject has received enzyme-inducing anti-epileptic agents within 14 days of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone).",
            "criterions": [
                {
                    "exact_snippets": "received enzyme-inducing anti-epileptic agents within 14 days of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone)",
                    "criterion": "enzyme-inducing anti-epileptic agent use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure greater than New York Heart Association (NYHA) Class II according to the NYHA Functional Classification.",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure greater than New York Heart Association (NYHA) Class II according to the NYHA Functional Classification.",
                    "criterion": "congestive heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject has received any of the following prior anticancer therapy:",
            "criterions": [
                {
                    "exact_snippets": "The subject has received any of the following prior anticancer therapy",
                    "criterion": "prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients whose only lesion undergoing resection has received stereotactic radiation within the past 3 months",
            "criterions": [
                {
                    "exact_snippets": "only lesion undergoing resection",
                    "criterion": "lesion undergoing resection",
                    "requirements": [
                        {
                            "requirement_type": "uniqueness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has received stereotactic radiation within the past 3 months",
                    "criterion": "stereotactic radiation to lesion undergoing resection",
                    "requirements": [
                        {
                            "requirement_type": "treatment_received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time_since_treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients receiving UGT1A1 (Uridine diphosphate glucuronosyl transferase 1A1) inhibitors or inducers.",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving UGT1A1 (Uridine diphosphate glucuronosyl transferase 1A1) inhibitors or inducers.",
                    "criterion": "UGT1A1 inhibitor or inducer use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Marked Baseline prolonged QT/QTc interval (ie, a repeated demonstration of a QTc interval >500 ms) demonstrated on ECG at Screening.",
            "criterions": [
                {
                    "exact_snippets": "Marked Baseline prolonged QT/QTc interval (ie, a repeated demonstration of a QTc interval >500 ms) demonstrated on ECG at Screening.",
                    "criterion": "QT/QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ms"
                            }
                        },
                        {
                            "requirement_type": "demonstration",
                            "expected_value": "repeated"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at Screening"
                        },
                        {
                            "requirement_type": "method of assessment",
                            "expected_value": "ECG"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any medical or other condition which, in the opinion of the Investigator, causes the subject to be medically unfit to receive Sacituzumab Govitecan, or unsuitable for any other reason.",
            "criterions": [
                {
                    "exact_snippets": "Any medical or other condition which, in the opinion of the Investigator, causes the subject to be medically unfit to receive Sacituzumab Govitecan",
                    "criterion": "medical or other condition",
                    "requirements": [
                        {
                            "requirement_type": "fitness for Sacituzumab Govitecan",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unsuitable for any other reason",
                    "criterion": "suitability for study participation",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug",
                    "criterion": "biologic agent administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant ECG abnormality, including:",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant ECG abnormality",
                    "criterion": "ECG abnormality",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of risk factors for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT Syndrome).",
            "criterions": [
                {
                    "exact_snippets": "History of risk factors for torsade de pointes (eg, heart failure",
                    "criterion": "heart failure",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of risk factors for torsade de pointes (eg, ... hypokalemia",
                    "criterion": "hypokalemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of risk factors for torsade de pointes (eg, ... family history of long QT Syndrome",
                    "criterion": "long QT Syndrome",
                    "requirements": [
                        {
                            "requirement_type": "family history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with Sacituzumab Govitecan",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with Sacituzumab Govitecan",
                    "criterion": "prior treatment with Sacituzumab Govitecan",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of significant cardiovascular disease, defined as:",
            "criterions": [
                {
                    "exact_snippets": "History of significant cardiovascular disease",
                    "criterion": "significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}